One of the most common questions researchers ask before starting a retatrutide protocol is a simple one: how much will it actually cost per month? The answer depends entirely on the weekly dose — and the difference between low-dose and high-dose protocols can be significant. Here's an honest breakdown of the numbers.
The Starting Point: A Single Vial
Retatrutide from Aussie Peptides is supplied as a lyophilised powder at 10mg per vial, priced at $139.99 AUD. That 10mg is your total usable quantity per vial, and it's the baseline from which all protocol costs are calculated.
In Phase 2 clinical trials (the most cited reference point in the research community), retatrutide was studied at weekly doses of 2mg, 4mg, 8mg, and 12mg. The dose-dependent response was clear: higher doses produced more substantial weight reductions, but each step up also increases how quickly you work through a vial.
Monthly Cost by Protocol Dose
The following breakdown is based on a standard four-week research month, using the Phase 2 trial dose groups as reference points. All figures use a single 10mg vial at $139.99.
Monthly cost estimated as: (4 doses/month × weekly dose) ÷ 10mg × $139.99. Figures are for research planning reference only.
The Starter Bundle Option
For researchers beginning a lower-dose protocol, the Retatrutide Starter Bundle at $269.99 AUD provides 2×10mg vials plus bacteriostatic water, insulin syringes, and alcohol swabs — everything required to start reconstitution from day one. At the 2mg/week protocol level, two vials covers 10 weeks of research, bringing the effective cost down versus purchasing single vials.
The bundle saves $35.97 versus buying components separately, and removes the friction of sourcing supplies from multiple orders.
Why Researchers Ask "Price Per Month"
The "per month" framing comes from the pharmaceutical world, where GLP-1 medications like Ozempic and Mounjaro are prescribed on monthly repeat scripts. Retatrutide is not available as a prescription medication in Australia — it is a research compound supplied for in-vitro laboratory and research use only, not for human consumption.
The per-month cost calculation is still useful as a research budgeting framework, since most multi-week research protocols are planned over monthly windows. It maps cleanly onto how researchers think about ongoing supply requirements.
Phase 2 Trial Context
The dose groups referenced above come from the Eli Lilly Phase 2 trial published in the New England Journal of Medicine (2023). [1] Key findings at 48 weeks:
- 2mg dose — mean body weight reduction of ~8.7%
- 4mg dose — mean body weight reduction of ~17.3%
- 8mg dose — mean body weight reduction of ~22.8%
- 12mg dose — mean body weight reduction of ~24.2%, with no plateau observed at week 48
The dose-dependent response makes clear why higher doses produce more significant outcomes — and why understanding the cost implications at each dose level matters when planning a structured research program.
Domestic Supply: No Import Delays
All Retatrutide supplied by Aussie Peptides ships domestically from within Australia. There are no customs delays, no import duties, and no international freight uncertainty. Every batch undergoes third-party analysis and a Certificate of Analysis is available to view for each lot.
References
- Jastreboff et al. — Triple Hormone Receptor Agonist (Retatrutide) for Obesity — A Phase 2 Trial, NEJM (2023)
- Lilly Press Release — TRIUMPH-4 Phase 3 Topline Results, December 2025
⚠ All information is for educational and research purposes only. Retatrutide is supplied for in-vitro research and laboratory use only. Not for human consumption.
